×
For best experience we recommend to activate Javascript in your browser.
Recombinant IL13 (Tralokinumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
Product Details anti-IL13 (Tralokinumab Biosimilar) Antibody
(hide)
Target
See all IL13 (Tralokinumab Biosimilar) products
IL13 (Tralokinumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for IL13 (Tralokinumab Biosimilar) antibodies
Mammalian Cells
Clonality
All clonalities for IL13 (Tralokinumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for IL13 (Tralokinumab Biosimilar) antibodies
This IL13 (Tralokinumab Biosimilar) antibody is un-conjugated
Application
ELISA
Purpose
Tralokinumab Biosimilar - Anti-IL13 mAb
Characteristics
Antibody Type: IgG4-lambda
Grade
Research Grade
Isotype
IgG4 lambda
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Buffer
PBS pH 7.5
Storage
-80 °C
Storage Comment
store at -80°C
Target Details for IL13 (Tralokinumab Biosimilar)
(hide)
Target
IL13 (Tralokinumab Biosimilar)
Abstract
IL13 (Tralokinumab Biosimilar) Products
Target Type
Biosimilar
Background
CAT-354 Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.
CAS-No
1044515-88-9
Recently viewed
(hide)